Date:11/6/2008

vaccine; whether USAMMDA will sponsor and the NMRC will complete preclinical and Phase 1 testing of a tetravalent, Vaxfectin(R)-formulated DNA vaccine for dengue; whether Vaxfectin(R) or other results in animal studies can be duplicated in human clinical trials; whether Vaxfectin(R) will improve the immune responses against the specific dengue vaccine targets; whether the dengue vaccine will be effective in protecting humans against dengue infection or disease; whether the dengue vaccine will achieve the safety and immunogenicity endpoints in the Phase 1 trial; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward- looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com

'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Promising Cystic Fibrosis Compound on Track for Development
3. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
4. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
5. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
8. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
9. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
10. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
11. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies